View Older Stories View More Recent Stories

May 19, 2015 07:05AM Amarantus to Present at Two Upcoming Investor Conferences
May 19, 2015 07:05AM Amarantus to Present at Two Upcoming Investor Conferences
May 15, 2015 08:05AM Amarantus Announces Successful Delivery and Distribution of MANF in Preclinical Model to Brain Areas Involved in Parkinson's Disease
May 15, 2015 08:05AM Amarantus Announces Successful Delivery and Distribution of MANF in Preclinical Model to Brain Areas Involved in Parkinson's Disease
May 14, 2015 08:05AM Amarantus Enters Into cGMP Manufacturing Agreement With Catalent Biologics for Production of MANF for Human Clinical Studies
May 14, 2015 08:05AM Amarantus Enters Into cGMP Manufacturing Agreement With Catalent Biologics for Production of MANF for Human Clinical Studies
May 13, 2015 01:00PM Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Proprietary Methods of Administration and Compositions in the Treatment of Parkinson's Disease
May 11, 2015 08:35AM Amarantus Reports Preliminary Data From Blood-based Version of MSPrecise(R) Diagnostic for Multiple Sclerosis
May 11, 2015 08:35AM Amarantus Reports Preliminary Data From Blood-based Version of MSPrecise(R) Diagnostic for Multiple Sclerosis
May 7, 2015 11:15AM Amarantus Announces the Presentation of Data Showing MANF's Positive Effect on Retinal Function at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 7, 2015 11:15AM Amarantus Announces the Presentation of Data Showing MANF's Positive Effect on Retinal Function at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 5, 2015 08:05AM Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Proprietary Compositions of Matter and Methods of Use for MANF
May 5, 2015 08:05AM Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Proprietary Compositions of Matter and Methods of Use for MANF
Apr 29, 2015 07:05AM Amarantus Granted European Union Orphan Drug Designation for MANF for the Treatment of Retinitis Pigmentosa
Apr 29, 2015 07:05AM Amarantus Granted European Union Orphan Drug Designation for MANF for the Treatment of Retinitis Pigmentosa
Apr 27, 2015 07:05AM Amarantus Closes $5 Million Preferred Stock Financing
Apr 27, 2015 07:05AM Amarantus Closes $5 Million Preferred Stock Financing
Apr 7, 2015 06:00AM Amarantus Reports 2014 Financial Results and Business Overview
Apr 7, 2015 06:00AM Amarantus Reports 2014 Financial Results and Business Overview
Mar 26, 2015 10:00AM Amarantus BioScience Opens Investigational New Drug (IND) Application With the U.S. Food and Drug Administration Allowing the Start of a Phase 2b Program of Eltoprazine in Parkinson's Disease Lev
Mar 23, 2015 08:05AM Amarantus to Present at the Neurotech Investing and Partnering Conference on Tuesday, April 7, 2015
Mar 23, 2015 08:05AM Amarantus to Present at the Neurotech Investing and Partnering Conference on Tuesday, April 7, 2015
Feb 23, 2015 08:30AM Amarantus to Present Positive Alzheimer's Disease Biomarker Data on the LymPro Test(R) at the 12th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologi
Feb 10, 2015 06:00AM Amarantus Announces Publication in BRAIN of Eltoprazine Phase 2a Clinical Study for Treating Parkinson's Disease Levodopa-Induced Dyskinesia
Feb 3, 2015 08:05AM Amarantus to Present at the 17th Annual BIO CEO & Investor Conference on February 10, 2015
Jan 15, 2015 06:15AM Amarantus Announces Exclusive Option Agreement With Georgetown University to License Patent Rights for Blood Based Biomarkers for Alzheimer's Disease
Jan 13, 2015 09:31AM Amarantus to Present at Noble Financial Capital Markets' Eleventh Annual Investor Conference
Dec 23, 2014 04:00PM Amarantus Receives Orphan Drug Designation for MANF From U.S. Food and Drug Administration for Treatment of Retinitis Pigmentosa
Dec 22, 2014 07:00AM Amarantus Commences Launch of Proprietary Alzheimer's Blood Diagnostic LymPro Test(R) to Pharmaceutical Industry for Use in Clinical Trials
Dec 19, 2014 07:35AM Amarantus Submits Orphan Drug Designation Application to US FDA for Treatment of Retinal Artery Occlusion With Product Candidate MANF
Dec 19, 2014 07:00AM Amarantus Announces Second Closing of Series E Preferred Financing
Dec 11, 2014 08:00AM Amarantus Appoints Elise Brownell, Ph.D., as Senior Vice President of Operations and Project Management
Dec 8, 2014 08:00AM Amarantus Appoints Renowned Drug Development Expert and Co-Founder of Amgen, Joseph Rubinfeld, Ph.D., to Its Board of Directors
Nov 25, 2014 09:17AM Amarantus Announces Positive Preclinical Data on the Effects of MANF on Vision in a Model of Retinitis Pigmentosa
Nov 17, 2014 04:05PM Amarantus Enters Into Exclusive Option Agreement to Acquire Engineered Skin Substitute for the Treatment of Severe Burns From Lonza
Oct 16, 2014 09:30AM Amarantus Applies to FDA for MANF Orphan Drug Designation in Retinitis Pigmentosa
Oct 9, 2014 06:00AM Amarantus Announces Positive LP-002 Data for Alzheimer's Blood Diagnostic LymPro Test(R)
Oct 7, 2014 08:00AM Amarantus Investigator Presents Positive MANF Animal Data in Central Retinal Vein Occlusion and Glaucoma at the Targeting Ocular Disorders Conference
Sep 29, 2014 02:03PM Amarantus Requests Pre-IND Feedback From FDA for Eltoprazine Phase IIb Parkinson's Disease Levodopa-Induced Dyskinesia Clinical Trial
Sep 25, 2014 04:00PM Amarantus Shareholders Approve All Matters Voted Upon at Annual Shareholders Meeting
Sep 12, 2014 10:30AM Amarantus Completes Enrollment of 72 Patient LP-002 Clinical Study for Alzheimer's Blood Diagnostic LymPro Test(R)
Sep 10, 2014 01:00PM Amarantus to Present Orphan Ocular Data at Targeting Ocular Disorders Conference 2014
Sep 9, 2014 08:30AM Amarantus Announces Positive MANF Ocular Toxicology Data
Sep 4, 2014 09:00AM Amarantus to Present at Sachs Associates 14th Annual Biotech in Europe Forum for Global Partnering and Investment
Sep 2, 2014 06:00AM Amarantus Initiates CLIA Development of Alzheimer's Blood Diagnostic LymPro Test(R) at ICON Central Laboratories
Aug 29, 2014 07:56AM Amarantus Appoints Iain Ross to Board of Directors
Aug 19, 2014 08:41AM Amarantus to Present at Upcoming Investor Conferences
Aug 15, 2014 08:10AM Amarantus Exercises Option to License Intellectual Property From University of Miami Bascom Palmer Eye Institute for Use of MANF in Retinal Disorders
Aug 1, 2014 09:25AM Amarantus Announces Positive Top-Line Interim Clinical Data for Alzheimer's Blood Diagnostic LymPro Test(R)
Jul 31, 2014 10:48AM The 3rd Alzheimer's-Focused #C4CT Concussion Summit Convenes Today at the United Nations
View More Recent Stories View Older Stories